New hope for Tough-to-Treat lymphoma: experimental drug BR101801 enters phase 2
NCT ID NCT07180771
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests an experimental drug called BR101801 in 44 people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to standard treatments. The main goal is to see how many patients have their tumors shrink or disappear. Participants must be well enough to carry out daily activities and have a life expectancy of at least 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.